{"id":"W2891596347","doi":"10.1186/s13045-018-0661-x","title":"A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis","year":2018,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Fondazione Regionale per la Ricerca Biomedica; F. Hoffmann-La Roche","keywords":"Ruxolitinib; Vismodegib; Myelofibrosis; Medicine; Internal medicine; Hematology; Oncology; Phases of clinical research; Clinical trial; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001586472,0.001079938,0.001680717,0.0003307608,0.0004346288,0.0007661329,0.0007405183,0.0009795005,0.004868818],"category_scores_gemma":[0.0008563673,0.0004759913,0.001086145,0.0002985001,0.0007463721,0.0007541318,0.0003403737,0.002633234,0.001166606],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008235347,"about_ca_system_score_gemma":0.001693481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006446058,"about_ca_topic_score_gemma":0.001266666,"domain_scores_codex":[0.9995582,0.0001883487,0.00002976805,0.00008522563,0.00004173216,0.00009680392],"domain_scores_gemma":[0.9991232,0.0001112411,0.0001462136,0.00007467523,0.00004875898,0.0004959684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7187463,0.1032557,0.01395303,0.0007028269,0.001183603,0.0004533393,0.0002743138,0.001903082,0.06634849,0.00028426,0.004289589,0.08860555],"study_design_scores_gemma":[0.4170984,0.5603527,0.01379334,0.00004100801,0.0004302911,0.0004389366,0.00004188482,0.0009547977,0.004203874,0.0001514043,0.00247059,0.00002263995],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920564,0.001229537,0.0006772534,0.0003151768,0.00006658496,0.002915405,0.0008421572,0.00007530701,0.001822119],"genre_scores_gemma":[0.9907831,0.0006199425,0.001740711,0.0006518878,0.0001065812,0.003011958,0.001823204,0.0000185288,0.001244184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004868818,"threshold_uncertainty_score":0.0162878,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02247277291908018,"score_gpt":0.331314420234806,"score_spread":0.3088416473157258,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}